Jove
Visualize
Contact Us

Related Experiment Videos

Tipranavir (Aptivus): approval cautiously recommended.

John S James

    AIDS Treatment News
    |July 29, 2005
    PubMed
    Summary

    A novel protease inhibitor effective against drug-resistant HIV strains is nearing US approval. This advancement offers new hope for patients with treatment-experienced HIV.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Activism and online fundraising: overview.

    AIDS treatment news·2007
    Same author

    "Fundathon": toward massively multiplayer online fundraising games.

    AIDS treatment news·2007
    Same authorSame journal

    Selling digital art in bulk through prepaid URLs.

    AIDS treatment news·2007
    Same authorSame journal

    Financial accounts that can reproduce, inherit, and evolve.

    AIDS treatment news·2007
    Same authorSame journal

    AIDS search engine wanted: what to do now?

    AIDS treatment news·2007
    Same author

    Prisoner death rate very high immediately after release.

    AIDS treatment news·2007
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Virology
    • Drug Discovery
    • Immunology

    Background:

    • The emergence of drug-resistant human immunodeficiency virus (HIV) strains poses a significant challenge to current antiretroviral therapy.
    • Existing protease inhibitors (PIs) are crucial components of HIV treatment regimens, but resistance can limit their efficacy.

    Discussion:

    • A new protease inhibitor demonstrating broad activity against a majority of HIV variants, including those resistant to existing PIs, has been evaluated.
    • The drug's efficacy and safety profile were assessed by an advisory committee, with a strong positive recommendation for approval.

    Key Insights:

    • The new protease inhibitor exhibits potent activity against a wide spectrum of HIV protease mutations.
    • Clinical data suggests favorable tolerability and a manageable safety profile in patients with treatment-experienced HIV.

    Outlook:

    • Anticipated US approval of this novel PI is expected to expand treatment options for individuals with multidrug-resistant HIV.
    • This development could significantly improve treatment outcomes and quality of life for a vulnerable patient population.

    Related Experiment Videos